Hyperlipidemia Overview and the Clinical and Economic Burden

Stream links:

1PM ET: https://globalmeet.webcasts.com/starthere.jsp?ei=1707428&tp_key=f86653ae2e

8PM ET: https://globalmeet.webcasts.com/starthere.jsp?ei=1707429&tp_key=0014ebc817

This activity is part 1 of a 3-part webinar curriculum. Click here to view the other webinars in this curriculum.

Program Description
Hyperlipidemia may occur due to genetic or acquired disorders that increase lipid and low-density lipoprotein cholesterol (LDL-C) levels. Elevated LDL-C is a well-established risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Treating hyperlipidemia should be contingent on numerous factors, including patient age, comorbidities, risk-enhancing factors, secondary causes, and shared decision-making measures that consider patient preferences. It is imperative that pharmacists understand that each patient’s LDL-C goal is contingent upon their overall cardiovascular risk. This webinar will review evidence-based recommendations for screening patients with risk factors for hyperlipidemia and reducing the risk of ASCVD. Recommended LDL-C target levels and the consequences associated with undiagnosed and untreated hyperlipidemia will be outlined.

Target Audience: Community pharmacists, health system pharmacists, and specialty pharmacists

Type of Activity: Application
Release date: March 25, 2025
Expiration date: May 25, 2025
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain approaches to treat associated comorbidities in patients with hyperlipidemia
• Identify the importance of lipoprotein(a) and low-density lipoprotein cholesterol lowering in reducing risk for cardiovascular events and complications

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-9999-25-009-L01-P. The activity is available for CE credit through May 25, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Dave L. Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS , has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Boehringer Ingelheim, Inc.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms